Perspectives on the discovery of small-molecule modulators for epigenetic processes

Journal of Biomolecular Screening

Volumn 17, Issue 5, 2012, Pages 555-571

  Lu, Quinn ^a   Quinn, Amy M ^a   Patel, Mehul P ^a   Semus, Simon F ^a   Graves, Alan P ^a   Bandyopadhyay, Deepak ^a   Pope, Andrew J ^a   Thrall, Sara H ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

epigenetic modulation; high throughput screen; hit identification strategy; protein protein interaction

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BIOLOGICAL FACTOR; CHEMICAL AGENT; DNA METHYLTRANSFERASE; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; PROTEIN ARGININE METHYLTRANSFERASE; REGULATOR PROTEIN; ROMIDEPSIN; SMALL MOLECULE EPIGENETIC MODULATOR; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VORINOSTAT;

DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE CONTROL; GENE TARGETING; HIGH THROUGHPUT SCREENING; HISTONE ACETYLATION; HISTONE CODE; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION;

DRUG DISCOVERY; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONES; HUMANS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES;

EID: 84861826096     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112437763     Document Type: Review

References (149)

1. Bunnage M. E.. Getting Pharmaceutical R&D Back on Target. Nat. Chem. Biol. 2011 ; 7: 335-339
2. Cressey D.. Traditional Drug-Discovery Model Ripe for Reform. Nature. 2011 ; 471: 17-18
3. Pammolli F., Magazzini L., Riccaboni M.. The Productivity Crisis in Pharmaceutical R&D. Nat. Rev. Drug Discov. 2011 ; 10: 428-438
4. Hopkins A. L., Groom C. R.. The Druggable Genome. Nat. Rev. Drug Discov. 2002 ; 1: 727-730
5. Russ A. P., Lampel S.. The Druggable Genome: An Update. Drug Discov. Today. 2005 ; 10: 1607-1610
6. Wang G. G., Allis C. D., Chi P.. Chromatin Remodeling and Cancer, Part I: Covalent Histone Modifications. Trends Mol. Med. 2007 ; 13: 363-372
7. Wang G. G., Allis C. D., Chi P.. Chromatin Remodeling and Cancer, Part II: ATP-Dependent Chromatin Remodeling. Trends Mol. Med. 2007 ; 13: 373-380
8. Szyf M.. Epigenetics, DNA Methylation, and Chromatin Modifying Drugs. Annu. Rev. Pharmacol. Toxicol. 2009 ; 49: 243-263
9. Mills A. A.. Throwing the Cancer Switch: Reciprocal Roles of Polycomb and Trithorax Proteins. Nat. Rev. Cancer. 2010 ; 10: 669-682
10. Lee J. S., Smith E., Shilatifard A.. The Language of Histone Crosstalk. Cell. 2010 ; 142: 682-685
11. Yun M., Wu J., Workman J. L., Li B.. Readers of Histone Modifications. Cell Res. 2011 ; 21: 564-578
12. Beck S., Rakyan V. K.. The Methylome: Approaches for Global DNA Methylation Profiling. Trends Genet. 2008 ; 24: 231-237
13. Malecova B., Morris K. V.. Transcriptional Gene Silencing through Epigenetic Changes Mediated by Non-coding RNAs. Curr. Opin. Mol. Ther. 2010 ; 12: 214-222
14. Koziol M. J., Rinn J. L.. RNA Traffic Control of Chromatin Complexes. Curr. Opin. Genet. Dev. 2010 ; 20: 142-148
15. Gluckman P. D., Hanson M. A., Buklijas T., Low F. M., Beedle A. S.. Epigenetic Mechanisms That Underpin Metabolic and Cardiovascular Diseases. Nat. Rev. Endocrinol. 2009 ; 5: 401-408
16. Rajasekhar V. K., Begemann M.. Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective. Stem Cells. 2007 ; 25: 2498-2510
17. Gasser S. M. E. Progress in Drug Research 67. Li E., ed. Springer: New York ; 2011 :
18. Albert M., Helin K.. Histone Methyltransferases in Cancer. Semin. Cell Dev. Biol. 2010 ; 21: 209-220
19. Jones P. A., Taylor S. M.. Cellular Differentiation, Cytidine Analogs and DNA Methylation. Cell. 1980 ; 20: 85-93
20. Santi D. V., Norment A., Garrett C. E.. Covalent Bond Formation between a DNA-Cytosine Methyltransferase and DNA Containing 5-Azacytosine. Proc. Natl. Acad. Sci. U. S. A. 1984 ; 81: 6993-6997
21. Kelly T. K., De Carvalho D. D., Jones P. A.. Epigenetic Modifications as Therapeutic Targets. Nat. Biotechnol. 2010 ; 28: 1069-1078
22. Wang M., Mok M. W., Harper H., Lee W. H., Min J., Knapp S., Oppermann U., Marsden B., Schapira M.. Structural Genomics of Histone Tail Recognition. Bioinformatics. 2010 ; 26: 2629-2630
23. Quinn A. M., Simeonov A.. Methods for Activity Analysis of the Proteins That Regulate Histone Methylation. Curr. Chem. Genomics. 2011 ; 5: 95-105
24. Janzen W. P., Wigle T. J., Jin J., Frye S. V.. Epigenetics: Tools and Technologies. Drug Discov. Today Technol. 2010 ; 7: e59 - e65
25. Chung C. W., Witherington J.. Progress in the Discovery of Small-Molecule Inhibitors of Bromodomain-Histone Interactions. J. Biomol. Screen. 2011 ; 16: 1170-1185
26. Philpott M., Yang J., Tumber T., Fedorov O., Uttarkar S., Filippakopoulos P., Picaud S., Keates T., Felletar I., Ciulli A., Knapp S., Heightman T. D.. Bromodomain-Peptide Displacement Assays for Interactome Mapping and Inhibitor Discovery. Mol. Biosyst. 2011 ; 7: 2899-2908
27. Ahrens T., Bergner A., Sheppard D., Hafenbradl D.. Efficient Hit-Finding Approaches for Histone Methyltransferases: The Key Parameters. J. Biomol. Screen. 2011 ; 17: 85-98
28. Foulks J. M., Parnell K. M., Nix R. N., Chau S., Swierczek K., Saunders M., Wright K., Hendrickson T. F., Ho K. K., McCullar M. V., Kanner S. B.. Epigenetic Drug Discovery: Targeting DNA Methyltransferases. J. Biomol. Screen. 2011 ; 17: 2-17
29. Eglen R. M., Reisine T.. Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome: An Overview. J. Biomol. Screen. 2011 ; 16: 1137-1152
30. Taverna S. D., Li H., Ruthenburg A. J., Allis C. D., Patel D. J.. How Chromatin-Binding Modules Interpret Histone Modifications: Lessons from Professional Pocket Pickers. Nat. Struct. Mol. Biol. 2007 ; 14: 1025-1040
31. Ruthenburg A. J., Li H., Patel D. J., Allis C. D.. Multivalent Engagement of Chromatin Modifications by Linked Binding Modules. Nat. Rev. Mol. Cell Biol. 2007 ; 8: 983-994
32. Sanchez R., Zhou M. M.. The Role of Human Bromodomains in Chromatin Biology and Gene Transcription. Curr. Opin. Drug Discov. Devel. 2009 ; 12: 659-665
33. Ocker M., Schneider-Stock R.. Histone Deacetylase Inhibitors: Signalling Towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 2007 ; 39: 1367-1374
34. Marks P. A., Xu W. S.. Histone Deacetylase Inhibitors: Potential in Cancer Therapy. J. Cell Biochem. 2009 ; 107: 600-608
35. Ungerstedt J. S., Sowa Y., Xu W. S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P. A.. Role of Thioredoxin in the Response of Normal and Transformed Cells to Histone Deacetylase Inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2005 ; 102: 673-678
36. Zhang C., Richon V., Ni X., Talpur R., Duvic M.. Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action. J. Invest. Dermatol. 2005 ; 125: 1045-1052
37. Bieliauskas A. V., Pflum M. K.. Isoform-Selective Histone Deacetylase Inhibitors. Chem. Soc. Rev. 2008 ; 37: 1402-1413
38. Balasubramanian S., Verner E., Buggy J. J.. Isoform-Specific Histone Deacetylase Inhibitors: The Next Step?. Cancer Lett. 2009 ; 280: 211-221
39. Avvakumov N., Cote J.. The MYST Family of Histone Acetyltransferases and Their Intimate Links to Cancer. Oncogene. 2007 ; 26: 5395-5407
40. Ghizzoni M., Haisma H. J., Maarsingh H., Dekker F. J.. Histone Acetyltransferases Are Crucial Regulators in NF-kappaB Mediated Inflammation. Drug Discov. Today. 2011 ; 16: 504-511
41. Lau O. D., Kundu T. K., Soccio R. E., Ait-Si-Ali S., Khalil E. M., Vassilev A., Wolffe A. P., Nakatani Y., Roeder R. G., Cole P. A.. HATs Off: Selective Synthetic Inhibitors of the Histone Acetyltransferases p300 and PCAF. Mol. Cell. 2000 ; 5: 589-595
42. Bowers E. M., Yan G., Mukherjee C., Orry A., Wang L., Holbert M. A., Crump N. T., Hazzalin C. A., Liszczak G., Yuan H., Larocca C., Saldanha S. A., Abagyan R., Sun Y., Meyers D. J., Marmorstein R., Mahadevan L. C., Alani R. M., Cole P. A.. Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor. Chem. Biol. 2010 ; 17: 471-482
43. Ferguson A. D., Larsen N. A., Howard T., Pollard H., Green I., Grande C., Cheung T., Garcia-Arenas R., Cowen S., Wu J., Godin R., Chen H., Keen N.. Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure. 2011 ; 19: 1262-1273
44. Kubicek S., O'Sullivan R. J., August E. M., Hickey E. R., Zhang Q., Teodoro M. L., Rea S., Mechtler K., Kowalski J. A., Homon C. A., Kelly T. A., Jenuwein T.. Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase. Mol. Cell. 2007 ; 25: 473-481
45. Chang Y., Zhang X., Horton J. R., Upadhyay A. K., Spannhoff A., Liu J., Snyder J. P., Bedford M. T., Cheng X.. Structural Basis for G9a-Like Protein Lysine Methyltransferase Inhibition by BIX-01294. Nat. Struct. Mol. Biol. 2009 ; 16: 312-317
46. Liu F., Chen X., Allali-Hassani A., Quinn A. M., Wigle T. J., Wasney G. A., Dong A., Senisterra G., Chau I., Siarheyeva A., Norris J. L., Kireev D. B., Jadhav A., Herold J. M., Janzen W. P., Arrowsmith C. H., Frye S. V., Brown P. J., Simeonov A., Vedadi M., Jin J.. Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem. 2010 ; 53: 5844-5857
47. Sack J. S., Thieffine S., Bandiera T., Fasolini M., Duke G. J., Jayaraman L., Kish K. F., Klei H. E., Purandare A. V., Rosettani P., Troiani S., Xie D., Bertrand J. A.. Structural Basis for CARM1 Inhibition by Indole and Pyrazole Inhibitors. Biochem. J. 2011 ; 17: 331-339
48. Daigle S. R., Olhava E. J., Therkelsen C. A., Majer C. R., Sneeringer C. J., Song J., Johnston L. D., Scott M. P., Smith J. J., Xiao Y., Jin L., Kuntz K. W., Chesworth R., Moyer M. P., Bernt K. M., Tseng J. C., Kung A. L., Armstrong S. A., Copeland R. A., Richon V. M., Pollock R. M.. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. Cancer Cell. 2011 ; 20: 53-65
49. Lee M. G., Wynder C., Schmidt D. M., McCafferty D. G., Shiekhattar R.. Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications. Chem. Biol. 2006 ; 13: 563-567
50. Suzuki T., Miyata N.. Lysine Demethylases Inhibitors. J. Med. Chem. 2011 ; 54: 8236-8250
51. Huang Y., Greene E., Murray S. T., Goodwin A. C., Baylin S. B., Woster P. M., Casero R. A.. Inhibition of Lysine-Specific Demethylase 1 by Polyamine Analogues Results in Reexpression of Aberrantly Silenced Genes. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 8023-8028
52. Huang Y., Stewart T. M., Wu Y., Baylin S. B., Marton L. J., Perkins B., Jones R. J., Woster P. M., Casero R. A.. Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes. Clin. Cancer Res. 2009 ; 15: 7217-7228
53. Sharma S. K., Wu Y., Steinbergs N., Crowley M. L., Hanson A. S., Casero R. A., Woster P. M.. (Bis)urea and (bis)thiourea Inhibitors of Lysine-Specific Demethylase 1 as Epigenetic Modulators. J. Med. Chem. 2010 ; 53: 5197-5212
54. Luo X., Liu Y., Kubicek S., Myllyharju J., Tumber A., Ng S., Che K. H., Podoll J., Heightman T. D., Oppermann U., Schreiber S. L., Wang X.. A Selective Inhibitor and Probe of the Cellular Functions of Jumonji C Domain-Containing Histone Demethylases. J. Am. Chem. Soc. 2011 ; 133: 9451-9456
55. Chang K. H., King O. N., Tumber A., Woon E. C., Heightman T. D., McDonough M. A., Schofield C. J., Rose N. R.. Inhibition of Histone Demethylases by 4-carboxy-2,2′-bipyridyl compounds. Chem. Med. Chem. 2011 ; 6: 759-764
56. King O. N., Li X. S., Sakurai M., Kawamura A., Rose N. R., Ng S. S., Quinn A. M., Rai G., Mott B. T., Beswick P., Klose R. J., Oppermann U., Jadhav A., Heightman T. D., Maloney D. J., Schofield C. J., Simeonov A.. Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors. PLoS. One. 2010 ; 5: e15535
57. Hamada S., Suzuki T., Mino K., Koseki K., Oehme F., Flamme I., Ozasa H., Itoh Y., Ogasawara D., Komaarashi H., Kato A., Tsumoto H., Nakagawa H., Hasegawa M., Sasaki R., Mizukami T., Miyata N.. Design, Synthesis, Enzyme-Inhibitory Activity, and Effect on Human Cancer Cells of a Novel Series of Jumonji Domain-Containing Protein 2 Histone Demethylase Inhibitors. J. Med. Chem. 2010 ; 53: 5629-5638
58. Rose N. R., Ng S. S., Mecinovic J., Lienard B. M., Bello S. H., Sun Z., McDonough M. A., Oppermann U., Schofield C. J.. Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases. J. Med. Chem. 2008 ; 51: 7053-7056
59. Juttermann R., Li E., Jaenisch R.. Toxicity of 5-aza-2′- Deoxycytidine to Mammalian Cells Is Mediated Primarily by Covalent Trapping of DNA Methyltransferase Rather Than DNA Demethylation. Proc. Natl. Acad. Sci. U. S. A. 1994 ; 91: 11797-11801
60. Medina-Franco J. L., Caulfield T.. Advances in the Computational Development of DNA Methyltransferase Inhibitors. Drug Discov. Today. 2011 ; 16: 418-425
61. Hewings D. S., Wang M., Philpott M., Fedorov O., Uttarkar S., Filippakopoulos P., Picaud S., Vuppusetty C., Marsden B., Knapp S., Conway S. J., Heightman T. D.. 3,5-Dimethylisoxazoles Act as Acetyl-Lysine-Mimetic Bromodomain Ligands. J. Med. Chem. 2011 ; 54: 6761-6770
62. Campagna-Slater V. R., Schapira M.. Finding Inspiration in the Protein Data Bank to Chemically Antagonize Readers of the Histone Code. Mol. Inform. 2010 ; 29: 322-331
63. Herold J. M., Wigle T. J., Norris J. L., Lam R., Korboukh V. K., Gao C., Ingerman L. A., Kireev D. B., Senisterra G., Vedadi M., Tripathy A., Brown P. J., Arrowsmith C. H., Jin J., Janzen W. P., Frye S. V.. Small-Molecule Ligands of Methyl-Lysine Binding Proteins. J. Med. Chem. 2011 ; 54: 2504-2511
64. Clark M. A., Acharya R. A., rico-Muendel C. C., Belyanskaya S. L., Benjamin D. R., Carlson N. R., Centrella P. A., Chiu C. H., Creaser S. P., Cuozzo J. W., Davie C. P., Ding Y., Franklin G. J., Franzen K. D., Gefter M. L., Hale S. P., Hansen N. J., Israel D. I., Jiang J., Kavarana M. J., Kelley M. S., Kollmann C. S., Li F., Lind K., Mataruse S., Medeiros P. F., Messer J. A., Myers P., O'Keefe H., Oliff M. C., Rise C. E., Satz A. L., Skinner S. R., Svendsen J. L., Tang L., van V. K., Wagner R. W., Yao G., Zhao B., Morgan B. A.. Design, Synthesis and Selection of DNA-Encoded Small-Molecule Libraries. Nat. Chem. Biol. 2009 ; 5: 647-654
65. Sun C., Petros A. M., Hajduk P. J.. Fragment-Based Lead Discovery: Challenges and Opportunities. J. Comput. Aided Mol. Des. 2011 ; 25: 607-610
66. Fry D. C.. Protein-Protein Interactions as Targets for Small Molecule Drug Discovery. Biopolymers. 2006 ; 84: 535-552
67. Berg T.. Small-Molecule Inhibitors of Protein-Protein Interactions. Curr. Opin. Drug Discov. Devel. 2008 ; 11: 666-674
68. Ofran Y., Rost B.. Protein-Protein Interaction Hotspots Carved into Sequences. PLoS. Comput. Biol. 2007 ; 3: e119
69. Kortemme T., Baker D.. A Simple Physical Model for Binding Energy Hot Spots in Protein-Protein Complexes. Proc. Natl. Acad. Sci. U. S. A. 2002 ; 99: 14116-14121
70. JACM. Ban Y.-E. A. Edelsbrunner H. Rudolph J., ed. 2006: 361-378.
71. Guney E., Tuncbag N., Keskin O., Gursoy A.. HotSprint: Database of Computational Hot Spots in Protein Interfaces. Nucleic Acids Res. 2008 ; 36: D662 - D666
72. Kumar M. D., Bava K. A., Gromiha M. M., Prabakaran P., Kitajima K., Uedaira H., Sarai A.. ProTherm and ProNIT: Thermodynamic Databases for Proteins and Protein-Nucleic Acid Interactions. Nucleic Acids Res. 2006 ; 34: D204 - D206
73. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A.. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science. 2004 ; 303: 844-848
74. He M. M., Smith A. S., Oslob J. D., Flanagan W. M., Braisted A. C., Whitty A., Cancilla M. T., Wang J., Lugovskoy A. A., Yoburn J. C., Fung A. D., Farrington G., Eldredge J. K., Day E. S., Cruz L. A., Cachero T. G., Miller S. K., Friedman J. E., Choong I. C., Cunningham B. C.. Small-Molecule Inhibition of TNF-alpha. Science. 2005 ; 310: 1022-1025
75. Viaud J., Zeghouf M., Barelli H., Zeeh J. C., Padilla A., Guibert B., Chardin P., Royer C. A., Cherfils J., Chavanieu A.. Structure-Based Discovery of an Inhibitor of Arf Activation by Sec7 Domains through Targeting of Protein-Protein Complexes. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 10370-10375
76. Wanner J., Fry D. C., Peng Z., Roberts J.. Druggability Assessment of Protein-Protein Interfaces. Future. Med. Chem. 2011 ; 3: 2021-2038
77. Fuller J. C., Burgoyne N. J., Jackson R. M.. Predicting Druggable Binding Sites at the Protein-Protein Interface. Drug Discov. Today. 2009 ; 14: 155-161
78. Laurie A. T., Jackson R. M.. Q-SiteFinder: An Energy-Based Method for the Prediction of Protein-Ligand Binding Sites. Bioinformatics. 2005 ; 21: 1908-1916
79. Hajduk P. J., Huth J. R., Fesik S. W.. Druggability Indices for Protein Targets Derived from NMR-Based Screening Data. J. Med. Chem. 2005 ; 48: 2518-2525
80. Landon M. R., Lancia D. R., Yu J., Thiel S. C., Vajda S.. Identification of Hot Spots within Druggable Binding Regions by Computational Solvent Mapping of Proteins. J. Med. Chem. 2007 ; 50: 1231-1240
81. Mattos C., Bellamacina C. R., Peisach E., Pereira A., Vitkup D., Petsko G. A., Ringe D.. Multiple Solvent Crystal Structures: Probing Binding Sites, Plasticity and Hydration. J. Mol. Biol. 2006 ; 357: 1471-1482
82. Seco J., Luque F. J., Barril X.. Binding Site Detection and Druggability Index from First Principles. J. Med. Chem. 2009 ; 52: 2363-2371
83. Sugaya N., Ikeda K.. Assessing the Druggability of Protein-Protein Interactions by a Supervised Machine-Learning Method. BMC. Bioinform. 2009 ; 10: 263
84. Heinke R., Carlino L., Kannan S., Jung M., Sippl W.. Computer- and Structure-Based Lead Design for Epigenetic Targets. Bioorg. Med. Chem. 2011 ; 19: 3605-3615
85. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W. B., Fedorov O., Morse E. M., Keates T., Hickman T. T., Felletar I., Philpott M., Munro S., McKeown M. R., Wang Y., Christie A. L., West N., Cameron M. J., Schwartz B., Heightman T. D., La T. N., French C. A., Wiest O., Kung A. L., Knapp S., Bradner J. E.. Selective Inhibition of BET Bromodomains. Nature. 2010 ; 468: 1067-1073
86. Chung C. W., Coste H., White J. H., Mirguet O., Wilde J., Gosmini R. L., Delves C., Magny S. M., Woodward R., Hughes S. A., Boursier E. V., Flynn H., Bouillot A. M., Bamborough P., Brusq J. M., Gellibert F. J., Jones E. J., Riou A. M., Homes P., Martin S. L., Uings I. J., Toum J., Clement C. A., Boullay A. B., Grimley R. L., Blandel F. M., Prinjha R. K., Lee K., Kirilovsky J., Nicodeme E.. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. J. Med. Chem. 2011 ; 54: 3827-3838
87. Izzo A., Schneider R.. Chatting Histone Modifications in Mammals. Brief. Funct. Genomics. 2010 ; 9: 429-443
88. Zeng L., Zhang Q., Li S., Plotnikov A. N., Walsh M. J., Zhou M. M.. Mechanism and Regulation of Acetylated Histone Binding by the Tandem PHD Finger of DPF3b. Nature. 2010 ; 466: 258-262
89. Lewis J. A., Lebois E. P., Lindsley C. W.. Allosteric Modulation of Kinases and GPCRs: Design Principles and Structural Diversity. Curr. Opin. Chem. Biol. 2008 ; 12: 269-280
90. Goodey N. M., Benkovic S. J.. Allosteric Regulation and Catalysis Emerge via a Common Route. Nat. Chem. Biol. 2008 ; 4: 474-482
91. Kuriyan J., Eisenberg D.. The origin of protein interactions and allostery in colocalization. Nature. 2007 ; 450: 983-990
92. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., Jones R. S., Zhang Y.. Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing. Science. 2002 ; 298: 1039-1043
93. Xu C., Bian C., Yang W., Galka M., Ouyang H., Chen C., Qiu W., Liu H., Jones A. E., MacKenzie F., Pan P., Li S. S., Wang H., Min J.. Binding of Different Histone Marks Differentially Regulates the Activity and Specificity of Polycomb Repressive Complex 2 (PRC2). Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 19266-19271
94. Margueron R., Justin N., Ohno K., Sharpe M. L., Son J., Drury W. J., Voigt P., Martin S. R., Taylor W. R., De M. V, Pirrotta V., Reinberg D., Gamblin S. J.. Role of the Polycomb Protein EED in the Propagation of Repressive Histone Marks. Nature. 2009 ; 461: 762-767
95. Han Z., Xing X., Hu M., Zhang Y., Liu P., Chai J.. Structural Basis of EZH2 Recognition by EED. Structure. 2007 ; 15: 1306-1315
96. Allali-Hassani A., Wasney G. A., Siarheyeva A., Hajian T., Arrowsmith C. H., Vedadi M.. Fluorescence-Based Methods for Screening Writers and Readers of Histone Methyl Marks. J. Biomol. Screen. 2011 ; 17: 71-84
97. Ruthenburg A. J., Wang W., Graybosch D. M., Li H., Allis C. D., Patel D. J., Verdine G. L.. Histone H3 Recognition and Presentation by the WDR5 Module of the MLL1 Complex. Nat. Struct. Mol. Biol. 2006 ; 13: 704-712
98. Patel A., Dharmarajan V., Cosgrove M. S.. Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide. J. Biol. Chem. 2008 ; 283: 32158-32161
99. Song J. J., Kingston R. E.. WDR5 Interacts with Mixed Lineage Leukemia (MLL) Protein via the Histone H3-Binding Pocket. J. Biol. Chem. 2008 ; 283: 35258-35264
100. Avdic V., Zhang P., Lanouette S., Groulx A., Tremblay V., Brunzelle J., Couture J. F.. Structural and Biochemical Insights into MLL1 Core Complex Assembly. Structure. 2011 ; 19: 101-108
101. Odho Z., Southall S. M., Wilson J. R.. Characterization of a Novel WDR5-Binding Site That Recruits RbBP5 through a Conserved Motif to Enhance Methylation of Histone H3 Lysine 4 by Mixed Lineage Leukemia Protein-1. J. Biol. Chem. 2010 ; 285: 32967-32976
102. Svedruzic Z. M., Reich N. O.. DNA Cytosine C5 Methyltransferase Dnmt1: Catalysis-Dependent Release of Allosteric Inhibition. Biochemistry. 2005 ; 44: 9472-9485
103. Chen Y., Yang Y., Wang F., Wan K., Yamane K., Zhang Y., Lei M.. Crystal Structure of Human Histone Lysine-Specific Demethylase 1 (LSD1). Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103: 13956-13961
104. Lee M. G., Wynder C., Cooch N., Shiekhattar R.. An Essential Role for CoREST in Nucleosomal Histone 3 Lysine 4 Demethylation. Nature. 2005 ; 437: 432-435
105. Metzger E., Wissmann M., Yin N., Muller J. M., Schneider R., Peters A. H., Gunther T., Buettner R., Schule R.. LSD1 Demethylates Repressive Histone Marks to Promote Androgen- Receptor-Dependent Transcription. Nature. 2005 ; 437: 436-439
106. Forneris F., Binda C., Vanoni M. A., Battaglioli E., Mattevi A.. Human Histone Demethylase LSD1 Reads the Histone Code. J. Biol. Chem. 2005 ; 280: 41360-41365
107. Clemons P. A.. Complex Phenotypic Assays in High-Throughput Screening. Curr. Opin. Chem. Biol. 2004 ; 8: 334-338
108. Richon V. M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R. A., Marks P. A.. Second Generation Hybrid Polar Compounds Are Potent Inducers of Transformed Cell Differentiation. Proc. Natl. Acad. Sci. U. S. A. 1996 ; 93: 5705-5708
109. Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A., Marks P. A.. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases. Proc. Natl. Acad. Sci. U. S. A. 1998 ; 95: 3003-3007
110. Grozinger C. M., Chao E. D., Blackwell H. E., Moazed D., Schreiber S. L.. Identification of a Class of Small Molecule Inhibitors of the Sirtuin Family of NAD-Dependent Deacetylases by Phenotypic Screening. J. Biol. Chem. 2001 ; 276: 38837-38843
111. Best A. M., Chang J., Dull A. B., Beutler J. A., Martinez E. D.. Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay. J. Biomed. Biotechnol. 2011 ; 2011: 868095
112. Stoops S. L., Pearson A. S., Weaver C., Waterson A. G., Days E., Farmer C., Brady S., Weaver C. D., Beauchamp R. D., Lindsley C. W.. Identification and Optimization of Small Molecules That Restore e-cadherin Expression and Reduce Invasion in Colorectal Carcinoma Cells. ACS Chem. Biol. 2011 ; 6: 452-465
113. Terstappen G. C., Schlupen C., Raggiaschi R., Gaviraghi G.. Target Deconvolution Strategies in Drug Discovery. Nat. Rev. Drug Discov. 2007 ; 6: 891-903
114. Saxena C.. Small-Molecule Affinity Chromatography Coupled Mass Spectrometry for Drug Target Deconvolution. Expert Opin. Drug Discov. 2011 ; 4: 701-714
115. Mann M.. Functional and Quantitative Proteomics Using SILAC. Nat. Rev. Mol. Cell Biol. 2006 ; 7: 952-958
116. Ong S. E., Schenone M., Margolin A. A., Li X., Do K., Doud M. K., Mani D. R., Kuai L., Wang X., Wood J. L., Tolliday N. J., Koehler A. N., Marcaurelle L. A., Golub T. R., Gould R. J., Schreiber S. L., Carr S. A.. Identifying the Proteins to Which Small-Molecule Probes and Drugs Bind in Cells. Proc. Natl. Acad. Sci. U. S. A. 2009 ; 106: 4617-4622
117. Bantscheff M., Scholten A., Heck A. J.. Revealing Promiscuous Drug-Target Interactions by Chemical Proteomics. Drug Discov. Today. 2009 ; 14: 1021-1029
118. Bantscheff M., Hopf C., Savitski M. M., Dittmann A., Grandi P., Michon A. M., Schlegl J., Abraham Y., Becher I., Bergamini G., Boesche M., Delling M., Dumpelfeld B., Eberhard D., Huthmacher C., Mathieson T., Poeckel D., Reader V., Strunk K., Sweetman G., Kruse U., Neubauer G., Ramsden N. G., Drewes G.. Chemoproteomics Profiling of HDAC Inhibitors Reveals Selective Targeting of HDAC Complexes. Nat. Biotechnol. 2011 ; 29: 255-265
119. Mittler G., Butter F., Mann M.. A SILAC-Based DNA Protein Interaction Screen That Identifies Candidate Binding Proteins to Functional DNA Elements. Genome Res. 2009 ; 19: 284-293
120. Ong S. E., Mittler G., Mann M.. Identifying and Quantifying In Vivo Methylation Sites by Heavy Methyl SILAC. Nat. Methods. 2004 ; 1: 119-126
121. Amanchy R., Kalume D. E., Iwahori A., Zhong J., Pandey A.. Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC). J. Proteome. Res. 2005 ; 4: 1661-1671
122. Fuchs S. M., Krajewski K., Baker R. W., Miller V. L., Strahl B. D.. Influence of Combinatorial Histone Modifications on Antibody and Effector Protein Recognition. Curr. Biol. 2011 ; 21: 53-58
123. Yang X., Lay F., Han H., Jones P. A.. Targeting DNA Methylation for Epigenetic Therapy. Trends Pharmacol. Sci. 2010 ; 31: 536-546
124. Bronner C., Chataigneau T., Schini-Kerth V. B., Landry Y.. The "Epigenetic Code Replication Machinery", ECREM: A Promising Drugable Target of the Epigenetic Cell Memory. Curr. Med. Chem. 2007 ; 14: 2629-2641
125. Swinney D. C., Anthony J.. How Were New Medicines Discovered?. Nat. Rev. Drug Discov. 2011 ; 10: 507-519
126. Sams-Dodd F.. Drug Discovery: Selecting the Optimal Approach. Drug Discov. Today. 2006 ; 11: 465-472
127. Goodman J. I., Augustine K. A., Cunnningham M. L., Dixon D., Dragan Y. P., Falls J. G., Rasoulpour R. J., Sills R. C., Storer R. D., Wolf D. C., Pettit S. D.. What Do We Need to Know Prior to Thinking about Incorporating an Epigenetic Evaluation into Safety Assessments?. Toxicol. Sci. 2010 ; 116: 375-381
128. Jirtle R. L., Skinner M. K.. Environmental Epigenomics and Disease Susceptibility. Nat. Rev. Genet. 2007 ; 8: 253-262
129. Whitelaw N. C., Whitelaw E.. Transgenerational Epigenetic Inheritance in Health and Disease. Curr. Opin. Genet. Dev. 2008 ; 18: 273-279
130. Stunkel W., Campbell R. M.. Sirtuin 1 (SIRT1): The Misunderstood HDAC. J. Biomol. Screen. 2011 ; 16: 1153-1169
131. Balasubramanyam K., Altaf M., Varier R. A., Swaminathan V., Ravindran A., Sadhale P. P., Kundu T. K.. Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression. J. Biol. Chem. 2004 ; 279: 33716-33726
132. Nicodeme E., Jeffrey K. L., Schaefer U., Beinke S., Dewell S., Chung C. W., Chandwani R., Marazzi I., Wilson P., Coste H., White J., Kirilovsky J., Rice C. M., Lora J. M., Prinjha R. K., Lee K., Tarakhovsky A.. Suppression of Inflammation by a Synthetic Histone Mimic. Nature. 2010 ; 468: 1119-1123
133. Ito T., Umehara T., Sasaki K., Nakamura Y., Nishino N., Terada T., Shirouzu M., Padmanabhan B., Yokoyama S., Ito A., Yoshida M.. Real-Time Imaging of Histone H4K12-Specific Acetylation Determines the Modes of Action of Histone Deacetylase and Bromodomain Inhibitors. Chem. Biol. 2011 ; 18: 495-507
134. Borah J. C., Mujtaba S., Karakikes I., Zeng L., Muller M., Patel J., Moshkina N., Morohashi K., Zhang W., Gerona-Navarro G., Hajjar R. J., Zhou M. M.. A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes. Chem. Biol. 2011 ; 18: 531-541
135. Fiskus W., Wang Y., Sreekumar A., Buckley K. M., Shi H., Jillella A., Ustun C., Rao R., Fernandez P., Chen J., Balusu R., Koul S., Atadja P., Marquez V. E., Bhalla K. N.. Combined Epigenetic Therapy with the Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin A and the Histone Deacetylase Inhibitor Panobinostat against Human AML cells. Blood. 2009 ; 114: 2733-2743
136. Bissinger E. M., Heinke R., Spannhoff A., Eberlin A., Metzger E., Cura V., Hassenboehler P., Cavarelli J., Schule R., Bedford M. T., Sippl W., Jung M.. Acyl Derivatives of p-Aminosulfonamides and Dapsone as New Inhibitors of the Arginine Methyltransferase hPRMT1. Bioorg. Med. Chem. 2011 ; 19: 3717-3731
137. Wan H., Huynh T., Pang S., Geng J., Vaccaro W., Poss M. A., Trainor G. L., Lorenzi M. V., Gottardis M., Jayaraman L., Purandare A. V.. Benzo[d]imidazole Inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)-Hit to Lead Studies. Bioorg. Med. Chem. Lett. 2009 ; 19: 5063-5066
138. Purandare A. V., Chen Z., Huynh T., Pang S., Geng J., Vaccaro W., Poss M. A., Oconnell J., Nowak K., Jayaraman L.. Pyrazole Inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 2008 ; 18: 4438-4441
139. Cheng D., Yadav N., King R. W., Swanson M. S., Weinstein E. J., Bedford M. T.. Small Molecule Regulators of Protein Arginine Methyltransferases. J. Biol. Chem. 2004 ; 279: 23892-23899
140. Spannhoff A., Heinke R., Bauer I., Trojer P., Metzger E., Gust R., Schule R., Brosch G., Sippl W., Jung M.. Target-Based Approach to Inhibitors of Histone Arginine Methyltransferases. J. Med. Chem. 2007 ; 50: 2319-2325
141. Liu F., Chen X., Allali-Hassani A., Quinn A. M., Wasney G. A., Dong A., Barsyte D., Kozieradzki I., Senisterra G., Chau I., Siarheyeva A., Kireev D. B., Jadhav A., Herold J. M., Frye S. V., Arrowsmith C. H., Brown P. J., Simeonov A., Vedadi M., Jin J.. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a. J. Med. Chem. 2009 ; 52: 7950-7953
142. Ceccaldi A., Rajavelu A., Champion C., Rampon C., Jurkowska R., Jankevicius G., Senamaud-Beaufort C., Ponger L., Gagey N., Dali A. H., Tost J., Vriz S., Ros S., Dauzonne D., Jeltsch A., Guianvarc'h D., Arimondo P. B.. C5-DNA Methyltransferase Inhibitors: From Screening to Effects on Zebrafish Embryo Development. Chembiochem. 2011 ; 12: 1337-1345
143. Stimson L., Rowlands M. G., Newbatt Y. M., Smith N. F., Raynaud F. I., Rogers P., Bavetsias V., Gorsuch S., Jarman M., Bannister A., Kouzarides T., McDonald E., Workman P., Aherne G. W.. Isothiazolones as Inhibitors of PCAF and p300 Histone Acetyltransferase Activity. Mol. Cancer Ther. 2005 ; 4: 1521-1532
144. Ueda R., Suzuki T., Mino K., Tsumoto H., Nakagawa H., Hasegawa M., Sasaki R., Mizukami T., Miyata N.. Identification of Cell-Active Lysine Specific Demethylase 1-Selective Inhibitors. J. Am. Chem. Soc. 2009 ; 131: 17536-17537
145. Hardcastle A., Tomlin P., Norris C., Richards J., Cordwell M., Boxall K., Rowlands M., Jones K., Collins I., McDonald E., Workman P., Aherne W.. A Duplexed Phenotypic Screen for the Simultaneous Detection of Inhibitors of the Molecular Chaperone Heat Shock Protein 90 and Modulators of Cellular Acetylation. Mol. Cancer Ther. 2007 ; 6: 1112-1122
146. Heinke R., Carlino L., Kannan S., Jung M., Sippl W.. Computer- and Structure-Based Lead Design for Epigenetic Targets. Bioorg. Med. Chem. 2011 ; 19: 3605-3615
147. Zeng L., Li J., Muller M., Yan S., Mujtaba S., Pan C., Wang Z., Zhou M. M.. Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association. J. Am. Chem. Soc. 2005 ; 127: 2376-2377
148. Sachchidanand , Resnick-Silverman L., Yan S., Mutjaba S., Liu W. J., Zeng L., Manfredi J. J., Zhou M. M.. Target Structure-Based Discovery of Small Molecules That Block Human p53 and CREB Binding Protein Association. Chem. Biol. 2006 ; 13: 81-90
149. Wigle T. J., Herold J. M., Senisterra G. A., Vedadi M., Kireev D. B., Arrowsmith C. H., Frye S. V., Janzen W. P.. Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen-Based Assay for Antagonists of Methyl-Lysine Binding Proteins. J. Biomol. Screen. 2010 ; 15: 62-71